Rep. Josh Gottheimer Buys Gilead Sciences, Inc. (NASDAQ:GILD) Stock

Representative Josh Gottheimer (Democratic-New Jersey) recently bought shares of Gilead Sciences, Inc. (NASDAQ:GILD). In a filing disclosed on February 26th, the Representative disclosed that they had bought between $1,001 and $15,000 in Gilead Sciences stock on January 27th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 1/30/2026.
• Sold $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 1/30/2026.
• Sold $1,001 – $15,000 in shares of Schneider National (NYSE:SNDR) on 1/26/2026.
• Purchased $1,001 – $15,000 in shares of Intercontinental Exchange (NYSE:ICE) on 1/26/2026.
• Sold $1,001 – $15,000 in shares of Nestle (OTCMKTS:NSRGY) on 1/26/2026.
• Sold $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 12/17/2025.
• Sold $1,001 – $15,000 in shares of Cheniere Energy (NYSE:LNG) on 12/12/2025.
• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 12/11/2025.
• Sold $15,001 – $50,000 in shares of Air Products and Chemicals (NYSE:APD) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Utz Brands (NYSE:UTZ) on 12/8/2025.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $150.03 on Tuesday. The company has a fifty day moving average of $136.62 and a two-hundred day moving average of $125.06. The company has a market capitalization of $186.25 billion, a PE ratio of 22.16, a P/E/G ratio of 1.95 and a beta of 0.36. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s payout ratio is currently 46.68%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for about $7.8 billion in cash, expanding its footprint into oncology and cell therapy and signaling diversification away from heavy HIV dependence — a material M&A catalyst that can re-rate growth expectations if integration and clinical progress succeed. Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance
• Positive Sentiment: Recent quarterly results beat consensus (EPS and revenue) and management set FY2026 EPS guidance in the $8.45–$8.85 range — evidence of steady cash generation and earnings visibility that supports valuation and the company’s ability to fund deals, buybacks and dividends. Gilead recent results and guidance
• Positive Sentiment: Gilead raised its quarterly dividend to $0.82 (ex-dividend March 13), increasing yield and returning cash to shareholders — supportive for income-focused investors and a sign of confidence in free cash flow. Gilead dividend announcement
• Neutral Sentiment: Positive analyst commentary and price-target raises have been published (multiple firms boosting targets), which can reinforce momentum but do not change fundamentals immediately.
• Neutral Sentiment: Gilead Foundation awarded $12M for HIV prevention efforts — good PR and mission-aligned but immaterial to near-term financials. Gilead Foundation Awards $12 Million
• Neutral Sentiment: Reported short-interest figures are effectively meaningless (showing zero in the available snapshot), so short-squeeze risk or bearish short pressure does not appear to be a driver today.
• Negative Sentiment: CEO Daniel O’Day sold 10,000 shares on Feb. 27 (about $1.45M at ~$144.79), one of several recent insider sales. While the sale is modest vs. his remaining stake and may be for liquidity/tax reasons, insider selling can spook some investors and is being highlighted in coverage. SEC Form 4 — Insider Sale

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the transaction, the chief financial officer directly owned 167,779 shares in the company, valued at approximately $25,910,110.97. The trade was a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the sale, the insider directly owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 309,280 shares of company stock worth $43,935,470. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on GILD shares. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research report on Thursday, January 8th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Sanford C. Bernstein restated an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a research note on Wednesday, February 11th. Finally, Bank of America set a $162.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $156.72.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Paulson Wealth Management Inc. raised its stake in shares of Gilead Sciences by 1.8% during the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares during the last quarter. Essex Financial Services Inc. grew its holdings in Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares during the period. Alpha Cubed Investments LLC raised its position in shares of Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 75 shares during the last quarter. Venture Visionary Partners LLC lifted its stake in shares of Gilead Sciences by 1.2% in the 4th quarter. Venture Visionary Partners LLC now owns 6,422 shares of the biopharmaceutical company’s stock valued at $788,000 after purchasing an additional 76 shares during the period. Finally, Moss Adams Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after purchasing an additional 76 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.